Samsung Biologics Co. approved a rights offering of approximately 3 trillion won, or $2.2 billion, on August 28, 2026, dedicating the bulk of proceeds to its pending acquisition of Swiss peptide CDMO PolyPeptide Group and the remainder to new manufacturing capacity at its Songdo Bio Campus II in Incheon. The board decision, reported by Bloomberg, converts a July acquisition agreement into a funded transaction and marks the largest biopharmaceutical deal in Korean corporate history.
Of the total raise, 2.7062 trillion won is allocated to the PolyPeptide purchase, priced at CHF 1.46 billion in the all-cash offer announced in July. The remaining 294.8 billion won will finance construction of Plant 6 and preparatory work for Plants 7 and 8 at the second campus, according to the company's announcement distributed through PR Newswire. CEO John Rim described the capital raise as the mechanism that "sets the stage for our next phase of growth," framing it as a move beyond the company's antibody contract-manufacturing base into peptide-based therapeutics, including GLP-1 receptor agonists.
What PolyPeptide Brings to the Ledger
Figure 1: The 3-trillion-won Samsung Biologics capital raise is allocated primarily to the PolyPeptide acquisition and partially to new Songdo Bio Campus II plants, with key rights-offering milestones through November.
PolyPeptide operates six manufacturing sites across France, Sweden, California, and India, making it one of the few pure-play peptide API producers in Western markets. The company recorded $444 million in revenue in 2025, a 15.6 percent increase over the prior year, driven largely by metabolic therapeutics. For Samsung Biologics, the acquisition internalizes custom peptide synthesis capacity that would otherwise require licensing from outside suppliers, consolidating solid-phase and liquid-phase production under a single corporate parent with deeper capital resources.
The transaction does not by itself resolve manufacturing-quality questions that attend the peptide supply chain. Purity specifications for high purity research peptides and therapeutic-grade material depend on process validation at individual sites, and no public filing reviewed for this report discloses PolyPeptide's specific impurity profiles or FDA inspection histories. Centralizing ownership may streamline technology transfer; it does not eliminate the solvent-intensive waste streams and cycle-time constraints inherent to industrial-scale peptide synthesis.
Dilution Pressure and the Rights-Offering Calendar
Investors priced the dilution immediately. Samsung Biologics shares fell 4.2 percent in early trading on August 28 to 1.527 million won on the Korea Exchange, and the decline widened to 6.78 percent by the session's close, with the stock settling at 1.486 million won, the Seoul Economic Daily reported. The company will issue 2.27 million new shares. Existing shareholders face proportional dilution unless they subscribe during the designated window.
The rights-offering structure means Samsung Biologics chose equity financing over debt, a decision the company framed as preserving balance-sheet flexibility amid intensifying CDMO competition. The record date falls on September 30, with new-share allocation set for October 6. Existing shareholders may subscribe November 9 and 10; unsubscribed shares go to a general public offering on November 12 and 13. New shares are targeted for listing on November 30, per the Korea Times.
Cross-Border Oversight and the Closing Window
Samsung Biologics expects to close the PolyPeptide acquisition by year-end 2026. Regulatory approval of the underlying deal remains subject to antitrust review in jurisdictions where both companies operate, though no specific agency objection has been made public as of August 28. The cross-border dimension places a Korean-domiciled parent over Swiss, French, Swedish, American, and Indian manufacturing sites, each subject to its national medicines regulator's good-manufacturing-practice oversight. Whether FDA, EMA, or India's Central Drugs Standard Control Organization will require supplementary facility filings or re-inspections post-closing has not been stated in any public document reviewed for this report.
Rim stated that the company will carry out "the PolyPeptide Group acquisition and the second bio campus expansion without setbacks to raise corporate value." The November 30 share listing and the December closing deadline will test that commitment against shareholder dilution pressure and any late-filed regulatory queries.
